Does dosing frequency of anti-CD20 therapies blunt vaccine responses and increase COVID-19 susceptibility in patients with multiple sclerosis?

Jagannadha Avasarala

doi:10.1111/bcp.16248

Does dosing frequency of anti-CD20 therapies blunt vaccine responses and increase COVID-19 susceptibility in patients with multiple sclerosis?

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	3094-3096
Number of pages	3
Journal	British Journal of Clinical Pharmacology
Volume	90
Issue number	12
DOIs	https://doi.org/10.1111/bcp.16248
State	Published - Dec 2024

Keywords

Anti-CD20 drugs
B cell repopulation
CD19 cell counts
COVID 19 susceptibility
dosing frequency
multiple sclerosis
vaccine response

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/bcp.16248

Cite this

@article{0e3a042e64a448748c32ca409c8e1f70,

title = "Does dosing frequency of anti-CD20 therapies blunt vaccine responses and increase COVID-19 susceptibility in patients with multiple sclerosis?",

keywords = "Anti-CD20 drugs, B cell repopulation, CD19 cell counts, COVID 19 susceptibility, dosing frequency, multiple sclerosis, vaccine response",

author = "Jagannadha Avasarala",

year = "2024",

month = dec,

doi = "10.1111/bcp.16248",

language = "English",

volume = "90",